Atorvastatin and Celecoxib in Combination Inhibits the Progression of Androgen-Dependent LNCaP Xenograft Prostate Tumors to Androgen Independence

Cancer Prevention Research - United States
doi 10.1158/1940-6207.capr-09-0059
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Enhanced Sensitivity to Androgen Withdrawal Due to Overexpression of Interleukin-6 in Androgen-Dependent Human Prostate Cancer LNCaP Cells

British Journal of Cancer
Cancer ResearchOncology
2009English

Androgen Upregulates the Palmitoylation of eIF3L in Human Prostate LNCaP Cells

OncoTargets and Therapy
OncologyPharmacology
2019English

Dysregulated Expression of Androgen-Responsive and Nonresponsive Genes in the Androgen-Independent Prostate Cancer Xenograft Model, CWR22-R

Nature Genetics
Genetics
2001English

Epidermal Growth Factor Receptor (ErbB1) Expression in Prostate Cancer Progression: Correlation With Androgen Independence

Prostate
OncologyUrology
2006English

The Radiation Response of Androgen-Refractory Prostate Cancer Cell Line C4-2 Derived From Androgen-Sensitive Cell Line LNCaP

Asian Journal of Andrology
MedicineUrology
2010English

5α-Reductase Inhibition Coupled With Short Off Cycles Increases Survival in the LNCaP Xenograft Prostate Tumor Model on Intermittent Androgen Deprivation Therapy

Journal of Urology
Urology
2015English

Tea Polyphenols Down-Regulate the Expression of the Androgen Receptor in LNCaP Prostate Cancer Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
2000English

Mathematical Modeling of Prostate Cancer Progression in Response to Androgen Ablation Therapy

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2011English

Silymarin Inhibits Function of the Androgen Receptor by Reducing Nuclear Localization of the Receptor in the Human Prostate Cancer Cell Line LNCaP

Carcinogenesis
MedicineCancer Research
2001English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy